Q3 organic growth accelerated to 9.2%, and management finally framed VBP 2.0 as a 5–15% price event rather than an open-ended risk. The CEO handoff is the wildcard.
STMN.SW · Earnings Call · 2026-10-28
The quarter was strong, but the framing was stronger
Straumann's Q3 2026 was, on its face, an acceleration story: organic growth of 9.2%, reported revenue of CHF 667.1 million, up 10.8% in Swiss francs, and just over CHF 2 billion for the first nine months at 8.3% organic. EMEA grew 10.5%, Asia Pacific 10.3%, North America 7.5% and Latin America 6.5%. That is broad-based, not a one-region beat. The company also confirmed its full-year outlook: high single-digit organic revenue growth and a core EBIT margin improvement of around 140 to 170 basis points at constant 2025 exchange rates. Good numbers. But the more important work on the call was analytical: management put a firmer boundary around the China VBP 2.0 risk and showcased a product cycle that could extend its premium implant moat into 2027.
China: from open-ended overhang to a bounded number
China has been the bear case for several quarters. In October 2025, management warned that “China and APAC will be moving in the negative side in the fourth quarter” — Guillaume Daniellot, CEO · 2025-10-30. In February 2026, the working assumption was still that “VBP will take place in the second quarter” — Guillaume Daniellot · 2026-02-18. Now the tender process is expected in Q1 2027. That is another timing slip, and it keeps the rules unknown for longer. Yet China actually returned to growth in Q3, at a high single-digit rate, and management expects strong double-digit growth in Q4 on an easier comparative base. The stock story is not simply "China is fixed" — it is that the price risk has been sized.
The key new disclosure is the private/public mix. Roughly 70% to 75% of Straumann's China business is private; only 25% is public hospitals where VBP applies in a mandatory way. Public VBP pricing has been around RMB 7,500 per single implant case, but private-sector pricing has already fallen to roughly RMB 4,000 to RMB 4,500 because of local competition. That means a VBP 2.0 cut in the public segment is cushioned by the fact that the private side is already priced well below the old public benchmark. Management now frames the total-portfolio price effect as a maximum 5% to 15% reduction.
When we are saying 5% to 15%, we are talking about what we expect as a consequence from our total portfolio from a price reduction standpoint.
That is a meaningful change in the debate. The old fear was that VBP 2.0 could gut China pricing; the new framing is that it is a bounded price event with volume offsets. It also explains why the private sector and different scenario language suddenly matters. The China campus and local manufacturing base give Straumann options: local production for the private market now, public VBP volumes once rules are set, and potentially Neodent by mid-2027. That does not make China risk-free, but it turns an open-ended overhang into a number investors can underwrite.
F.A.S.T, APS and the iEXCEL moat
The second pillar is product-led share gain. The freshest company-specific keywords this quarter are APS technology, F.A.S.T Full Arch and F.A.S.T Molar, all tied to the iEXCEL Implant system. Straumann has already sold more than 100,000 F.A.S.T Molar abutments. The new Full Arch workflow uses a SIRIOS intraoral scanner plus small reference components to capture implant positions immediately after surgery, replacing a costly dedicated scanning step. Management expects to launch it in North America and Europe in early January: “we expect to launch it by very early January in North America and Europe” — Guillaume Daniellot, CEO · 2026-10-28. That timing makes it a 2027 growth contributor, not a 2026 number.
The strategic point is that F.A.S.T is not priced as a separate premium product. It is designed to pull customers into the iEXCEL ecosystem and improve mix. The same logic applies to the scanner business: Straumann now has an installed base of more than 65,000 intraoral scanners, sold more units in the first nine months of 2026 than in all of 2025, and now sources roughly two-thirds of scanner units from its own brand. The margin implications are not subtle. On SIRIOS versus 3Shape, the CFO-equivalent claim was that gross margin is “twice as much at least when we compare the gross margin we are doing on SIRIOS versus 3Shape TRIOS technology” — Guillaume Daniellot, CEO · 2026-10-28. The AXS platform now has more than 20,000 regular active users, and management says those users are substantially more likely to reorder. That is a stickiness argument, not just a hardware argument.
North America, Latin America and the succession question
North America grew 7.5% in Q3 and 7.9% over nine months despite cautious consumer sentiment. Management's read is that patient flow has been stable and that the high-rate squeeze has already removed the credit-dependent Full Arch patient. As the CEO put it, “we have been playing in the high interest rate environment already for quite some time” — Guillaume Daniellot, CEO · 2026-10-28. That is an important reframing of the high interest theme and the broader global impact of high rates: the bad news is in the base, so incremental deterioration may be limited.
Latin America is messier. Q3 organic growth was 6.5%, though the first nine months were 12.1%. Brazil is roughly 80% of the region, and election-related uncertainty weighed on patient demand and orthodontic case volumes. Management expects a recovery and is leaning on the Hispanic hubs — Mexico, Colombia, Chile, Argentina — plus the Neodent GT Plus launch in mid-2027. The new Latin America keyword ranking reflects that this is now a live swing factor rather than a footnote. ClearCorrect is also improving at the margin: double-digit growth in its 14 priority markets and, notably, growth in North America in Q3. The U.S. is “definitely, I think, our #1 priority market” — Guillaume Daniellot, CEO · 2026-10-28, and breakeven is still targeted for the end of 2027. That contrasts with Align Technology's Clear Aligner ASP pressure, though Straumann's aligner business is subscale and still losing money.
The real wildcard is governance. This was Guillaume Daniellot's final earnings call before handing over to Christopher Norbye, and analysts immediately asked whether the midterm plan survives the transition. Daniellot insisted the 10% revenue CAGR and 40 to 50 basis points of annual margin expansion were Board-endorsed: “the midterm guidance has been obviously set ... with the Board” — Guillaume Daniellot, CEO · 2026-10-28. The midterm guidance keyword is now a top-five company theme precisely because the market wants to know whether the new CEO inherits a plan or a placeholder.
The debate has moved
Straumann did not eliminate China risk or macro risk this quarter. It did something more useful: it converted China from an open-ended pricing fear into a 5% to 15% total-portfolio price framework, and it showed that product innovation — APS, F.A.S.T Full Arch, iEXCEL, SIRIOS and AXS — can drive conversion and mix even in a sluggish market. The catalysts are now dated: F.A.S.T launches in early January, VBP rules arrive in Q1 2027, and ClearCorrect is meant to break even by the end of 2027. For an CHF 18.6 billion medtech, that is a credible de-risking. The remaining question is whether the departing CEO's flywheel keeps spinning under the new one.